Theresa Heggie
Net worth: 787 480 $ as of 2026-05-30
Net worth: 787 480 $ as of 2026-05-30
Ms. Theresa M.
Heggie is an Independent Director at BioCryst Pharmaceuticals, Inc. and a Co-Managing Director at Alnylam Germany GmbH.
She is on the Board of Directors at ProQR Therapeutics NV, BioCryst Pharmaceuticals, Inc. and Alnylam UK Ltd. Ms. Heggie was previously employed as a Chief Executive Officer & Director by Freeline Therapeutics Holdings Ltd., a Senior Vice President, Head-EMEA & Canada Region by Alnylam Pharmaceuticals, Inc., an Independent Non-Executive Director by Swedish Orphan Biovitrum AB, a Chief Marketing & Strategy Officer by The British United Provident Association Ltd., a Senior Vice President-Global Commercial Operations by TRANSKARYOTIC THERAPIES INC, a Chief Executive Officer by Jerini AG, a Senior Vice President-Global Commercial Operations by Shire Plc, a Vice President-Global Marketing by Baxter International, Inc., a Principal by Janssen Pharmaceuticals, Inc., a Principal by Ohmeda Pharmaceuticals, and a Chief Executive Officer by Spur Therapeutics Ltd. She received her undergraduate degree from Cornell University.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2026-06-10 | 80,646 ( 0.03% ) | 718 556 $ | 2026-05-30 | |
| 2026-03-17 | 43,623 ( 0.04% ) | 68 924 $ | 2026-05-30 |
| Companies | Position | Start |
|---|---|---|
| BIOCRYST PHARMACEUTICALS, INC. | Director/Board Member | 2018-12-02 |
| PROQR THERAPEUTICS N.V. | Director/Board Member | 2023-05-17 |
Alnylam Germany GmbH
Alnylam Germany GmbH BiotechnologyHealth Technology Engages in research, development, manufacturing and distribution of pharmaceutical products | Chief Executive Officer | - |
Alnylam UK Ltd.
Alnylam UK Ltd. BiotechnologyHealth Technology Develops biotechnology products | Director/Board Member | 2017-10-08 |
| Companies | Position | End |
|---|---|---|
| FREELINE THERAPEUTICS HOLDINGS PLC | Chief Executive Officer | 2021-08-14 |
| ALNYLAM PHARMACEUTICALS, INC. | Corporate Officer/Principal | 2020-04-30 |
| SWEDISH ORPHAN BIOVITRUM AB | Director/Board Member | 2017-04-09 |
The British United Provident Association Ltd.
The British United Provident Association Ltd. Life/Health InsuranceFinance Provides health insurance and consulting, dental & aged care services | Sales & Marketing | 2016-02-29 |
Shire Human Genetic Therapies, Inc.
Shire Human Genetic Therapies, Inc. Medical SpecialtiesHealth Technology Develops human genetic therapies | Corporate Officer/Principal | 2013-04-30 |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 16 |
|---|---|
Baxter International, Inc.
Baxter International, Inc. Medical SpecialtiesHealth Technology Produces and supplies medical products, healthcare systems, therapies and pharmaceuticals & provide kidney care services | Health Technology |
BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc. BiotechnologyHealth Technology Designs and develops oral small-molecule & injectable protein therapeutics | Health Technology |
Janssen Pharmaceuticals, Inc.
Janssen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets prescription drugs | Health Technology |
Shire Plc
Shire Plc Pharmaceuticals: MajorHealth Technology Develops and markets medicines for patients with rare diseases | Health Technology |
The British United Provident Association Ltd.
The British United Provident Association Ltd. Life/Health InsuranceFinance Provides health insurance and consulting, dental & aged care services | Finance |
Shire Orphan Therapies GmbH
Shire Orphan Therapies GmbH Pharmaceuticals: MajorHealth Technology Develops novel drugs | Health Technology |
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes therapeutics based on RNA interference | Health Technology |
Cornell University
Cornell University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Shire Human Genetic Therapies, Inc.
Shire Human Genetic Therapies, Inc. Medical SpecialtiesHealth Technology Develops human genetic therapies | Health Technology |
Ohmeda Pharmaceuticals | |
Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB Pharmaceuticals: MajorHealth Technology Manufactures and supplies pharmaceuticals and orphan drugs in the areas of hematology, immunology and specialty care | Health Technology |
ProQR Therapeutics NV
ProQR Therapeutics NV Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company with interest in the discovery and development of therapeutics for the treatment of genetic disorders | Health Technology |
Freeline Therapeutics Ltd.
Freeline Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company, which developing gene therapies for bleeding and other debilitating disorders | Health Technology |
Alnylam Germany GmbH
Alnylam Germany GmbH BiotechnologyHealth Technology Engages in research, development, manufacturing and distribution of pharmaceutical products | Health Technology |
Alnylam UK Ltd.
Alnylam UK Ltd. BiotechnologyHealth Technology Develops biotechnology products | Health Technology |
Freeline Therapeutics Holdings Plc
Freeline Therapeutics Holdings Plc BiotechnologyHealth Technology Develops and manufactures next-generation gene therapies | Health Technology |
Select your edition
All financial news and data tailored to specific country editions